Armune BioScience, Inc.
Armune BioScience was formed to develop and commercialize high value, protein signature-based diagnostic tests for prostate, lung and breast cancers that will allow physicians and patients to make better treatment decisions. Prostate cancer is the most prevalent cancer affecting men in the U.S. and it is estimated there will be 240,890 new cases diagnosed in 2011 and 32,000 deaths. It is also a major cause of death in Europe, with the U.S. and Western Europe accounting for 51% of the prostate cancer deaths in the world. The PSA (Prostate Specific Antigen) test is the primary prostate cancer diagnostic test used today, but under increasing scrutiny. The PSA test has good sensitivity but poor specificity resulting in many false positives and unnecessary biopsies.
The technology for diagnosing prostate cancer can also be used for early diagnosis of lung and breast cancer using blood. Lung cancer is the leading cause of cancer deaths and this represents a significant market opportunity.
Breast cancer is the second leading cause of cancer deaths in women today (after lung cancer) and is the most common cancer among women. Although breast cancer rates are rising in many western countries, deaths from the disease have decreased in some countries as a result of improved screening (mammography) and treatment. However, there are no serum-based breast cancer diagnostic tests available today.